Tunicamycin [11089-65-9]
Referentie HY-A0098-2mg
Formaat : 2mg
Merk : MedChemExpress
Description |
Tunicamycin is a mixture of homologous nucleoside antibiotic that inhibits N-linked glycosylation and blocks GlcNAc phosphotransferase (GPT). Tunicamycin causes accumulation of unfolded proteins in cell endoplasmic reticulum (ER) and induces ER stress, and causes blocking of DNA synthesis and cell cycle arrest in G1 phase. Tunicamycin inhibits gram-positive bacteria, yeasts, fungi, and viruses and has anti-cancer activity[1][2][3].Tunicamycin increases exosome release in cervical cancer cells[4]. |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
In Vitro |
Tunicamycin (2 μg/mL; 24 hours; CD44+/CD24- and original MCF7 cells) treatment increases the spliced XBP-1, ATF6 nuclear translocation level and CHOP protein expression in CD44+/CD24- and original MCF7 cells[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis
|
|||||||||
In Vivo | ||||||||||
Masse moléculaire |
844.94 (n=10) |
|||||||||
Formule |
C39H64N4O16 |
|||||||||
CAS No. | ||||||||||
Appearance |
Solid |
|||||||||
Color |
Off-white to light yellow |
|||||||||
SMILES |
O=C1NC(N([C@H]2[C@H](O)[C@H](O)[C@@H](C(C[C@@H]3[C@H](O)[C@H](O)[C@@H](NC(/C=C/[(CH2) 8-11]C(C)C)=O)[C@H](O[C@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4NC(C)=O)O3)O)O2)C=C1)=O |
|||||||||
Structure Classification | ||||||||||
Initial Source |
Streptomyces lysosuperficus |
|||||||||
Livraison | Room temperature in continental US; may vary elsewhere. |
|||||||||
Stockage |
|
|||||||||
Solvant et solubilité |
In Vitro:
DMSO : 33.33 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O : 10 mg/mL (adjust pH to 12 with 1 M NaOH) Ethanol : 1 mg/mL (ultrasonic and warming and heat to 60°C) Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
|
|||||||||
Pureté et documentation | ||||||||||
Références |
|